Apellis Pharmaceuticals Target Price

Where could APLS trade next? Consensus target price: $83.

Get informed when a big investor buys or sells

+ Follow

Share Price

$41.03

Average Target Price

$83.00

102.3% upside

1 analysts in the last 4 months

High: $83 | Low: $83

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-07-28	NeedhamJoseph Stringer	$83	102.3% upside
2026-04-17	Wells Fargo	$41	0.1% downside
2026-01-27	Barclays	$24	41.5% downside
2026-01-20	Wells Fargo	$26	36.6% downside
2026-01-13	Cantor Fitzgerald	$35	14.7% downside
2026-01-12	Goldman Sachs	$19	53.7% downside
2025-12-19	Stifel Nicolaus	$48	17% upside
2025-11-03	Mizuho SecuritiesGraig Suvannavejh	$19	53.7% downside
2025-10-31	Robert W. Baird	$52	26.7% upside
2025-10-31	H.C. Wainwright	$45	9.7% upside
2025-10-29	Mizuho Securities	$24	41.5% downside
2025-10-15	Wells Fargo	$32	22% downside
2025-09-26	Goldman Sachs	$18	56.1% downside
2025-07-30	Scotiabank	$22	46.4% downside
2024-11-06	H.C. WainwrightDouglas Tsao	$57	38.9% upside
2024-09-23	Robert W. BairdColleen Kusy	$92	124.2% upside
2024-09-20	Stifel NicolausAnnabel Samimy	$84	104.7% upside
2024-09-20	Mizuho SecuritiesGraig Suvannavejh	$39	4.9% downside
2024-09-16	Mizuho SecuritiesGraig Suvannavejh	$42	2.4% upside
2024-08-09	Robert W. BairdColleen Kusy	$96	134% upside
2024-08-08	JefferiesAkash Tewari	$82	99.9% upside
2024-08-02	H.C. WainwrightDouglas Tsao	$83	102.3% upside
2024-07-26	Robert W. BairdColleen Kusy	$86	109.6% upside
2024-07-01	Mizuho SecuritiesGraig Suvannavejh	$49	19.4% upside
2024-05-23	Wells FargoDerek Archila	$48	17% upside
2024-02-05	JefferiesAkash Tewari	$80	95% upside
2023-01-02	Wells FargoDerek Archila	$58	41.4% upside
2022-11-15	J.P. Morgan	$79	92.5% upside
2022-09-12	Wedbush	$67	63.3% upside
2022-09-08	Stifel Nicolaus	$65	58.4% upside
2022-08-18	Oppenheimer	$78	90.1% upside
2022-08-09	Credit Suisse	$52	26.7% upside
2022-08-09	Goldman Sachs	$102	148.6% upside
2022-08-09	Raymond James	$113	175.4% upside
2022-07-20	Citigroup	$86	109.6% upside
2022-06-23	Stifel NicolausAnnabel Samimy	$60	46.2% upside
2022-05-24	Goldman Sachs	$84	104.7% upside
2022-05-05	Credit Suisse	$44	7.2% upside
2022-05-05	Raymond James	$102	148.6% upside
2021-11-09	WedbushLaura Chico	$28	31.8% downside
2021-11-09	BMO CapitalMatthew Luchini	$69	68.2% upside
2021-10-01	Cantor FitzgeraldAlethia Young	$74	80.4% upside
2021-10-01	JefferiesChris Howerton	$74	80.4% upside
2021-09-10	Credit SuisseTiago Fauth	$38	7.4% downside
2021-07-01	Cowen & Co.Phil Nadeau	$70	70.6% upside

Apellis Pharmaceuticals (APLS) FAQ

Apellis Pharmaceuticals posts a target price of $83. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $83 for APLS means covering analysts, on average, see the stock 102.3% upside of $41.03 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for APLS's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Apellis Pharmaceuticals's other metric pages and overview cover the third.

Judging Apellis Pharmaceuticals against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $83 here, then scan peer and history charts to see if the gap is persistent.